A detailed history of Rhumbline Advisers transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 68,723 shares of OVID stock, worth $71,471. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,723
Previous 69,733 1.45%
Holding current value
$71,471
Previous $53,000 52.83%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$0.75 - $1.3 $757 - $1,313
-1,010 Reduced 1.45%
68,723 $81,000
Q2 2024

Aug 01, 2024

SELL
$0.7 - $3.34 $8,995 - $42,922
-12,851 Reduced 15.56%
69,733 $53,000
Q1 2024

May 09, 2024

BUY
$2.72 - $4.04 $7,936 - $11,788
2,918 Added 3.66%
82,584 $251,000
Q4 2023

Feb 08, 2024

SELL
$2.98 - $3.78 $9,312 - $11,812
-3,125 Reduced 3.77%
79,666 $256,000
Q3 2023

Nov 09, 2023

BUY
$3.23 - $3.97 $12,994 - $15,971
4,023 Added 5.11%
82,791 $317,000
Q2 2023

Aug 08, 2023

BUY
$2.53 - $3.89 $199,283 - $306,407
78,768 New
78,768 $258,000
Q2 2021

Aug 05, 2021

SELL
$3.3 - $4.49 $161,667 - $219,965
-48,990 Closed
0 $0
Q1 2021

May 06, 2021

SELL
$2.42 - $4.47 $1,645 - $3,039
-680 Reduced 1.37%
48,990 $197,000
Q4 2020

Feb 10, 2021

BUY
$2.28 - $6.84 $7,729 - $23,187
3,390 Added 7.32%
49,670 $115,000
Q3 2020

Nov 12, 2020

SELL
$5.39 - $8.24 $10,483 - $16,026
-1,945 Reduced 4.03%
46,280 $266,000
Q2 2020

Aug 13, 2020

BUY
$2.67 - $7.91 $128,760 - $381,459
48,225 New
48,225 $355,000
Q2 2019

Aug 14, 2019

SELL
$1.59 - $2.14 $27,045 - $36,401
-17,010 Closed
0 $0
Q1 2019

May 01, 2019

BUY
$1.77 - $3.56 $812 - $1,634
459 Added 2.77%
17,010 $30,000
Q4 2018

Jan 31, 2019

BUY
$2.42 - $6.6 $12,850 - $35,046
5,310 Added 47.24%
16,551 $40,000
Q3 2018

Nov 07, 2018

SELL
$5.6 - $11.0 $3,220 - $6,325
-575 Reduced 4.87%
11,241 $64,000
Q2 2018

Aug 06, 2018

BUY
$6.16 - $10.14 $72,786 - $119,814
11,816 New
11,816 $92,000

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $73.2M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.